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Chronic or acute insults to the myocardium are responsible for the onset of
cardiomyopathy and heart failure. Due to the poor regenerative ability of the human
adult heart, the survival of cardiomyocytes is a prerequisite to support heart function.
Chaperone proteins, by regulating sarcomeric protein folding, function, and turnover in
the challenging environment of the beating heart, play a fundamental role in myocardial
physiology. Nevertheless, a number of evidences indicate that, under stress conditions
or during cell damage, myocardial cells release chaperone proteins that, from the
extracellular milieu, play a detrimental function, by perpetuating inflammation and
inducing cardiomyocyte apoptosis. Blocking the activity of extracellular chaperones
has been proven to have beneficial effects on heart function in preclinical models
of myocardial infarction and cardiomyopathy. The application of this approach in
combination with tissue engineering strategies may represent a future innovation in
cardiac regenerative medicine.
Keywords: extracellular chaperones, HSPs, Toll-like receptors, sterile inflammation, myocardial infarction,
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INTRACELLULAR CHAPERONES
Sarcomere efficiency is a priority to maintain cardiac function. The impressive sarcomere structure
depends on the rigorous association of hundreds of proteins, held together by non-covalent
bonds in the challenging context of continuous contractions and relaxations. Indeed, the rhythmic
mechanical stretch of the beating heart is, per se, a source of protein unfolding and a number
of pathological factors, such as pressure overload, metabolic challenges, oxidative stress, may tip
the balance toward dysfunction. An efficient quality control mechanism is essential for sarcomere
maintenance and dynamic adaptation to new physiological conditions (Willis et al., 2009). Further,
unfolded protein degradation through the ubiquitin–proteasome pathway and autophagy (Ranek
et al., 2018) is crucial in protecting cardiomyocytes from the accumulation of dangerous protein
aggregates. Chaperone proteins are in charge of carrying out these essential tasks and monitoring
the efficiency of the entire contractile system. Chaperones have been originally discovered as
induced by hyperthermia, whereby the name of heat shock proteins (HSPs) has been attributed
to a number of chaperones (Schlesinger, 1990). Later, it became clear that several chaperones
are induced upon different types of stress stimuli, including oxidative stress, pathogen infection,
mechanical stress, hypoxic conditions, and ischemia (Sbroggio et al., 2008; Tarone and Brancaccio,
2014; Sorge and Brancaccio, 2016; Penna et al., 2018). Chaperones are divided in different
subfamilies depending on their structure, molecular weight and on their ability to hydrolyze
ATP (Macario and Conway de Macario, 2005; Kampinga et al., 2009). In this review, we will
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mention chaperones belonging to two subclasses: ATP-dependent
chaperones and small heat shock proteins (sHSPs), lacking
ATPase activity. The best known ATP-dependent chaperones are
the heat shock proteins HSP90, HSP70, and HSP60 (numbers are
indicative of their molecular weights). They bind to two classes
of proteins: substrate proteins and co-chaperones. Chaperone
binding allows substrate proteins, also called clients, to reach
their functional conformation, to refold after denaturation and
to be protected from degradation. Co-chaperones, instead, assist
chaperones in their function, favoring client protein recognition
and the transition toward the different structural states required
for binding and release of clients. The family of sHSPs is
characterized by the absence of ATPase activity, a lower molecular
weight, the presence of a highly conserved α-crystallin domain,
and their attitude to form oligomers (Carra et al., 2019; Haslbeck
et al., 2019). Both ATP-dependent chaperones and sHSPs play
a protective role in the myocardium thanks to their ability
to cope with protein misfolding, to promote unfolded protein
degradation and to support survival signaling in cardiomyocytes
(Willis and Patterson, 2013; Tarone and Brancaccio, 2014).
EXTRACELLULAR CHAPERONES
Chaperones are conventionally considered intracellular proteins,
prevalently located in the cytoplasm, in the endoplasmic
reticulum, in mitochondria, and in the nucleus. In addition
to their well-known roles inside the cells, some chaperones
and co-chaperones have been found to be secreted in the
extracellular milieu in response to cell stress, through an
unconventional secretory pathway, and to exert different
functions from the outside (Srivastava, 2002b; Calderwood,
2018; Pockley and Henderson, 2018). Among other activities,
extracellular chaperones work as damage-associated molecular
patterns (DAMPS). As for pathogen-associated molecular
patterns (PAMPs), DAMPs are recognized by pattern-recognition
receptors (PRRs), such as Toll-like receptors (TLRs), which, in
turn, trigger inflammatory responses. In addition to chaperones,
DAMPs include the high-mobility group box 1 (HMGB1),
S100 family of proteins, RNA, mitochondrial DNA, uric acid,
adenosine nucleotides, and others. These molecules may reach
the outside by a regulated unconventional secretion induced
by stress or may be released during cell damage. From the
extracellular milieu, they bind to PRRs on different cell types,
activate signaling pathways, and orchestrate cytokine production
and immune cell recruitment (Asea et al., 2000; Asea, 2003;
Bianchi, 2007). The release of DAMPs plays a role in different
diseases in which the immune system is actively involved,
including arthritis, multiple sclerosis, cancer, and cardiovascular
diseases (Roh and Sohn, 2018). Nevertheless, the release of
chaperones from stressed cells may represent an ancient and
evolutionary conserved protection mechanism against pathogen
infection (Srivastava, 2002a,b). Indeed, chaperones, by binding
antigenic peptides and interacting with receptors on antigen-
presenting cells, are crucial players in antigen internalization
and processing, contributing to innate and adaptive immune
responses. Stressful conditions and tissue necrosis, by mediating
chaperone release, trigger a sterile inflammation that, besides
clearing cellular debris, may extend organ damage and blunt
reparative responses (Lai et al., 2019).
The myocardium is composed of different cell types, whereas
cardiomyocytes and cardiac fibroblasts are the more represented,
endothelial cells, vessel smooth muscle cells, and immune cells
are also present in a relevant number. All these cell types
express PRRs able to sense DAMPS and detect cardiac stress and
damage. After myocardial infarction, the release of DAMPs from
injured cardiomyocytes results primarily in the recruitment and
activation of innate immune cells, causing endothelial damage
and cardiomyocyte injury (Arslan et al., 2011). Accordingly,
Toll-like receptor 2 (TLR2) and TLR4 null mice are protected
from ischemia–reperfusion injury (Sakata et al., 2007; Arslan
et al., 2010, 2011; Li et al., 2011). In addition, DAMPs promote
fibroblast proliferation, extracellular matrix deposition, and
secretion of metalloproteinases (MMPs) that may jeopardize the
stability of the scar (Turner, 2016). Overall, TLR signaling in
acute myocardial infarction has been convincingly associated to
a maladaptive remodeling and with a decreased cardiac function
(Shishido et al., 2003; Satoh et al., 2006b; Timmers et al., 2008;
Turner, 2016).
HSP70
HSP70 is an ubiquitously expressed chaperone that, inside the
cell, plays an essential role in mediating protein folding and
exerts a protective activity against hypoxic and ischemic events
(Hecker and McGarvey, 2011). Following different insults such
as ischemia, hypoxia, and hemodynamic overload, HSP70 and
its cognate protein HSC70 are upregulated in cardiomyocytes
and secreted or passively released. Indeed, in mice subjected
to abdominal aortic constriction, HSP70 accumulates on the
cardiomyocyte plasma membranes and in the mouse serum
in a time-dependent manner (Cai et al., 2010). Treatment of
mice with doxorubicin, a chemotherapy drug known to cause
cardiotoxicity, also induces HSP70 upregulation in the heart
and its subsequent accumulation on cardiomyocyte membranes
and mouse serum (Liu P. et al., 2019). Moreover, patients
experiencing cardiac arrest (Jenei et al., 2013a), acute myocardial
infarction (Dybdahl et al., 2005; Satoh et al., 2006a), or coronary
artery bypass grafting with the use of cardiopulmonary bypass
(Dybdahl et al., 2002) present a higher HSP70 level in the
serum, compared to healthy subjects. In these patients, higher
circulating levels of HSP70 correlate with increased serum
levels of proinflammatory cytokines such as IL-1α, IL-6, TNF-α,
IL-17, and TGF-β and myocardial necrosis markers, such as
creatine kinase and cardiac troponin T, and are associated with
an increased mortality during the follow-up period (Dybdahl
et al., 2002, 2005; Satoh et al., 2006a; Jenei et al., 2013a,b).
Primary isolated cardiomyocytes treated with recombinant
HSP70 proteins show an increase in NF-κB activity, a decreased
contractility and a raise in apoptotic death. Stimulation of
the cardiac muscle cell line HL-1 with recombinant HSP70
promotes the expression of inflammatory markers downstream
the p38 and the NF-κB signaling pathways. The activity of
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the recombinant HSP70 was totally impaired in TLR2 null
cardiomyocytes and in cardiomyocytes deficient for the TLR
signal adaptor protein MyD88 (Mathur et al., 2011). Similarly,
treatment of mouse cardiomyocytes with recombinant HSC70
induces the phosphorylation of p38; increases the expression of
mRNA coding for TNF-α, IL-1β, and IL-6; and depresses cardiac
contractility, in a TLR4-dependent manner (Zou et al., 2008; Ao
et al., 2009). Overall, these data suggest that once secreted, HSP70
and HSC70 bind to TLR2 and TLR4 expressed on cardiomyocytes
and induce the p38 MAPK and the NF-κB signaling pathways
(Figure 1). Due to the high expression of TLRs on immune
cells, it is not surprising that HSP70 and HSC70 possess a
potent immunomodulatory role in the myocardium, regulating
immune infiltration after stress stimuli. For instance, binding of a
recombinant HSP70 to TLR4 on peritoneal-derived macrophages
induces the production of TNF-α (Figure 1), which, in turn,
stokes chronic inflammation in the myocardium. In patients
with myocardial infarction, HSP70 serum levels are positively
correlated with the number of TLR4-positive monocytes in the
heart, which favor heart failure progression. The presence of
HSP70 in patients’ serum not only represents a reliable marker
in heart failure (Jenei et al., 2013b), but may also be exploited as
a target to treat cardiac pathologies. The functional antagonism
of the extracellular HSP70 (eHSP70), using anti-HSP70
antibodies, significantly attenuates cardiac hypertrophy, fibrosis,
and cardiomyocyte apoptosis induced by pressure overload.
Moreover, the treatment with HSP70-neutralizing antibodies
reduces pro-inflammatory M1 macrophage infiltration in the
myocardium, blunting chronic inflammation (Cai et al., 2010;
Liu P. et al., 2019). Injection of anti-HSP70 antibodies, after
doxorubicin treatment in mice, significantly counteracts α-SMA
and collagen-1 upregulation, two important markers of fibrosis
in the myocardium, and reduces the production of IL-6, TFG-β,
and IL-17A. At the same time, anti-HSP70 antibodies inhibit
the expression of inducible NO synthase and cyclooxygenase
2, suggesting that the chronic inflammation in the hearts of
doxorubicin-treated mice can be reversed by blocking eHSP70
activity (Liu P. et al., 2019). Similarly, treatment with anti-
HSC70 antibodies in mice subjected to ischemia/reperfusion
(I/R) improves post-ischemic cardiac functional recovery and
reduces the expression of proinflammatory cytokines (IL-6,
IL-1β, and TGF-β) (Zou et al., 2008), favoring cardiomyocyte
survival. Neutralizing antibodies against TLR2 and TLR4 mimic
the effect of HSP70/HSC70 blocking antibodies, preventing
reduction in fractional shortening and increasing heart function
(Mathur et al., 2011).
BAG3
Bcl-2-associated athanogene 3 (BAG3) plays crucial roles
in cardiomyocytes by inhibiting apoptosis and promoting
unfolded protein degradation through macroautophagy. Indeed,
mutations in the BAG3 coding gene are associated with dilated
cardiomyopathy (Liu L. et al., 2019). Besides this important
intracellular role, BAG3 has been found secreted by the rat
cardiomyoblast cell line H9c2 and by primary adult human
cardiomyocytes in response to stress stimuli and it is detectable
in the sera of heart failure patients (De Marco et al., 2013;
Gandhi et al., 2015). The extracellular BAG3 triggers the
PI3K/AKT/eNOS pathway in endothelial cells, causing nitric
oxide release and vasorelaxation (Carrizzo et al., 2016). Of note,
BAG3 secreted by cancer cells may activate macrophages and
promote IL-6 production, suggesting that BAG3 may regulate
inflammation also in the myocardial context (Rosati et al.,
2015). Further studies are awaited to define the impact of the
extracellular BAG3 on cardiac function after myocardial damage.
HSP90
HSP90 is an essential and ubiquitous chaperone that exerts
multiple roles inside the cells, ranging from protein folding,
buffering protein denaturation, and assisting signal transduction
protein conformational changes (Schopf et al., 2017). HSP90 is
secreted in response to different stress stimuli and, from the
extracellular milieu, it is able to bind to several cellular receptors,
among them TLR2 and 4, and to unleash intracellular signal
transduction pathways (Calderwood et al., 2007). The role of the
extracellular HSP90 (eHSP90) has been extensively studied in the
cancer microenvironment, where it regulates metalloproteinase
activity (Baker-Williams et al., 2019) and fibronectin matrix
assembly (Chakraborty et al., 2020) and promotes cancer cell
survival, migration, and invasion (Calderwood, 2018). In this
context, eHSP90 can also recruit and activate stromal fibroblasts
(Bohonowych et al., 2014; Tang et al., 2019). Garcia and
colleagues described cardiac fibroblasts as a primary source of
eHSP90 in the myocardium subjected to pressure overload.
Cardiac fibroblasts are activated by myocardial damage or stress
and are responsible for matrix deposition. eHSP90 has been
found to interact with the transforming growth factor-β receptor
I (TGFβRI) on the surface of cardiac fibroblasts, inducing TGF-
β signaling and promoting collagen production and fibrosis.
Indeed, mice null for the inducible HSP90α isoform show
reduced collagen deposition and cardiac fibrosis in long-term
pressure overload (Garcia et al., 2016; Figure 1).
HSP60
HSP60 is a chaperone protein located both in mitochondria
and in the cytosol, responsible for the folding of mitochondrial-
imported proteins (Singh et al., 1990; Brinker et al., 2001).
In mitochondria, HSP60 monomers assemble in a double
heptameric ring, associated with a co-chaperone, HSP10, that
caps the inner cavity and regulates substrate processing (Xu et al.,
1997). Instead, in the cytosol, HSP60 is present as a monomer
or bound to specific interactors, as the pro-apoptotic protein Bax
(Kirchhoff et al., 2002). Several studies demonstrated that the
expression and distribution of HSP60 is altered in cardiac diseases
(Novo et al., 2011). In a rat model of heart failure, HSP60 was
found upregulated after ligation of the left anterior descending
artery, together with proinflammatory cytokines, brain, and atrial
natriuretic peptides (Lin et al., 2007). In isolated cardiac myocytes
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FIGURE 1 | Chaperone proteins are released by cardiac cells and bind to surface receptors on different cell types, activating specific signaling pathways and
inducing apoptosis, chronic inflammation, and fibrosis.
subjected to ischemic insults, HSP60 translocates from the cytosol
to plasma membrane lipid rafts and is secreted and released in
exosomes (Gupta and Knowlton, 2002; Lin et al., 2007). HSP60
doubles in patients affected by ischemic disease, if compared
with healthy controls (Knowlton et al., 1998), and its membrane
translocation and release have been also demonstrated (Lin et al.,
2007; Tian et al., 2013). Moreover, HSP60 circulating levels
in patients with coronary artery disease and acute myocardial
infarction correlate with the extent of the disease (Mandal et al.,
2006; Novo et al., 2011).
The translocation of HSP60 to the plasma membrane and
its secretion induce the release of Bax that can move to
mitochondria and activate the apoptotic cascade (Gupta and
Knowlton, 2002). In addition, HSP60 actively triggers apoptosis
in cardiomyocytes from the extracellular compartment (Kim
et al., 2009; Li et al., 2011). Indeed, in adult-rat cardiomyocytes
or H9c2 cells, the extracellular HSP60 (eHSP60) binds to TLR4,
but not TLR2, and promotes the expression of TNF-α, IL-
6, and IL-1β (Kim et al., 2009; Tian et al., 2013; Figure 1).
Pretreatment of cells with blocking antibodies against TLR4
or inhibitors for MyD88 significantly decreases cardiomyocyte
apoptosis, while antibodies against TLR2 have no effect (Kim
et al., 2009). Antibodies against TNF-α, but not against IL-
1β, also block eHSP60-induced apoptosis (Kim et al., 2009).
All these evidence suggest that extracellular eHSP60 specifically
activates the TLR4-MyD88-NF-κB pathway, thus inducing
TNF-α-mediated cardiomyocyte apoptosis. In vivo coronary
artery ligation followed by reperfusion induces the activation of
the interleukin receptor-associated kinase-1 (IRAK-1), a kinase
critical for TLR signaling. The treatment of mice with anti-
HSP60 antibodies, prior to the ligation, significantly attenuates
IRAK-1 activation (Li et al., 2011). The absence of TLR4 or
MyD88, but not TLR2, impairs IRAK-1 activation in response
to I/R, confirming the specificity of eHSP60 in activating TLR4
signaling (Li et al., 2011). eHSP60 induces caspase-8-dependent
apoptosis and the absence of TLR4, or the treatment of mice with
anti-HSP60 antibodies, and attenuates I/R-induced cell death
(Li et al., 2011).
In endothelial cells, HSP60 elicits the expression of E-selectin,
ICAM-1, and VCAM-1, favoring the leukocyte trafficking within
the vascular wall (Kol et al., 1999). In macrophages, it has
been suggested that HSP60 binds to TLR2 and TLR4 and
triggers an intracellular signal via MyD88 and TRAF6 (Vabulas
et al., 2001), leading to the release of NO2−, the induction
of TNF-α and IL-6 and the overexpression of IL-12 and IL-
15 (Chen et al., 1999; Kol et al., 1999; Figure 1). HSP60
has also been found to localize in the atherosclerotic plaques,
where it can provoke the production of TNF-α and MMP9 by
macrophages (Kol et al., 1998). In addition, HSP60 can act as
an autoantigen during chronic inflammation, as suggested by
the presence of antibodies and T-cell responses to HSP60 in
various inflammatory conditions (Nomoto and Yoshikai, 1991;
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FIGURE 2 | The administration of neutralizing antibodies against extracellular chaperones, in conjunction with the implantation of engineered cardiac tissues, may
represent a new approach to dampen myocardial inflammation and improve the engraftment.
Res et al., 1991), causing cardiac decline (Ohashi et al., 2000;
Burian et al., 2001; Wysocki et al., 2002).
HSP27
HSP27 is a widely expressed chaperone protein belonging to
the small HSP family, exerting a number of protective function
in cardiomyocytes (Tarone and Brancaccio, 2014). Human and
murine hearts release HSP27 in the circulation after myocardial
infarction and I/R. Treatment of isolated mouse hearts with
HSP27 recombinant proteins induces NF-κB activation and IL-
6 production in the myocardium and causes a depression in
cardiac function. Treatment with recombinant HSP27 activates
an inflammatory response also in human and murine coronary
vascular endothelial cells, promoting the overexpression of
ICAM-1, MCP-1, IL-6, and IL-8 in a dose-dependent manner.
All these effects are mediated by TLR2 and 4, since the treatment
with HSP27 has no effect on cells derived from TLR2-null or
TLR4-defective mice (Figure 1). Of note, neutralizing antibodies
against HSP27 reduce myocardial NF-κB activity and IL-6
production and improve functional recovery after cardiac I/R
(Jin et al., 2014).
CONCLUSION
All the evidence discussed above indicate that chaperones
are actively secreted from stressed cells or released from
damaged cells during chronic and acute cardiac insults or
during clinical procedures like coronary artery bypass graft
(Westaby, 1987; Levy and Kelly, 1993; Szerafin et al., 2008;
Khan et al., 2014). Of note, the global inhibition of chaperone
functions in heart using small molecules able to cross the
plasma membrane would be seriously harmful, since chaperones
are crucial in maintaining cardiomyocyte proteostasis and in
sustaining heart function both in healthy conditions and during
pathological insults (Willis et al., 2009; Willis and Patterson, 2013;
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Tarone and Brancaccio, 2014; Sorge and Brancaccio, 2016; Penna
et al., 2018). A number of therapeutic antibodies have already
been approved for clinical applications and many are in late-
stage trials mainly to treat cancer and autoimmune diseases.
Antibodies may block the activity of extracellular proteins,
without affecting the intracellular counterparts (Redman et al.,
2015). Consistently, antibodies able to blunt the detrimental
activity of extracellular chaperones have been used successfully in
preclinical models of myocardial infarction and cardiomyopathy
(Zou et al., 2008; Cai et al., 2010; Li et al., 2011; Jin
et al., 2014; Liu P. et al., 2019). Research in developing
engineered heart tissues to improve myocardial regeneration
is an active field in regenerative medicine. The identification
of suitable biocompatible materials to be colonized with
functional cardiomyocytes is a promising strategy to heal
an organ with a very poor regenerative potential as the
human heart (Madonna et al., 2019). Nevertheless, human
cardiomyocytes subjected to stress locally activate innate and
adaptive immunity through chaperone release (Levy and Kelly,
1993; Veres et al., 2002; Wysocki et al., 2002; Mandal et al.,
2006; Szerafin et al., 2008; Novo et al., 2011). This chronic sterile
inflammation in the damaged myocardium may represent an
issue in engineered tissue engraftment, by promoting apoptosis
in colonizing cardiomyocytes and increasing the probability
of rejection. We propose that the inhibition of extracellular
chaperones during the implant of engineered heart tissues
may represent a new advance in improving grafting and heart
regeneration (Figure 2).
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